Cargando…
Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design
Ovarian cancer (OC) is highly lethal due to late detection and frequent recurrence. Initial treatments, comprising surgery and chemotherapy, lead to disease remission but are invariably associated with subsequent relapse. The identification of novel therapies and an improved understanding of the mol...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558812/ https://www.ncbi.nlm.nih.gov/pubmed/37810241 http://dx.doi.org/10.1016/j.isci.2023.107952 |
_version_ | 1785117363869319168 |
---|---|
author | Li, Yan-Ruide Ochoa, Christopher J. Zhu, Yichen Kramer, Adam Wilson, Matthew Fang, Ying Chen, Yuning Singh, Tanya Di Bernardo, Gabriella Zhu, Enbo Lee, Derek Moatamed, Neda A. Bando, Joanne Zhou, Jin J. Memarzadeh, Sanaz Yang, Lili |
author_facet | Li, Yan-Ruide Ochoa, Christopher J. Zhu, Yichen Kramer, Adam Wilson, Matthew Fang, Ying Chen, Yuning Singh, Tanya Di Bernardo, Gabriella Zhu, Enbo Lee, Derek Moatamed, Neda A. Bando, Joanne Zhou, Jin J. Memarzadeh, Sanaz Yang, Lili |
author_sort | Li, Yan-Ruide |
collection | PubMed |
description | Ovarian cancer (OC) is highly lethal due to late detection and frequent recurrence. Initial treatments, comprising surgery and chemotherapy, lead to disease remission but are invariably associated with subsequent relapse. The identification of novel therapies and an improved understanding of the molecular and cellular characteristics of OC are urgently needed. Here, we conducted a comprehensive analysis of primary tumor cells and their microenvironment from 16 chemonaive and 10 recurrent OC patient samples. Profiling OC tumor biomarkers allowed for the identification of potential molecular targets for developing immunotherapies, while profiling the microenvironment yielded insights into its cellular composition and property changes between chemonaive and recurrent samples. Notably, we identified CD1d as a biomarker of the OC microenvironment and demonstrated its targeting by invariant natural killer T (iNKT) cells. Overall, our study presents a comprehensive immuno-profiling of OC tumor and microenvironment during disease progression, guiding the development of immunotherapies for OC treatment, especially for recurrent disease. |
format | Online Article Text |
id | pubmed-10558812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-105588122023-10-08 Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design Li, Yan-Ruide Ochoa, Christopher J. Zhu, Yichen Kramer, Adam Wilson, Matthew Fang, Ying Chen, Yuning Singh, Tanya Di Bernardo, Gabriella Zhu, Enbo Lee, Derek Moatamed, Neda A. Bando, Joanne Zhou, Jin J. Memarzadeh, Sanaz Yang, Lili iScience Article Ovarian cancer (OC) is highly lethal due to late detection and frequent recurrence. Initial treatments, comprising surgery and chemotherapy, lead to disease remission but are invariably associated with subsequent relapse. The identification of novel therapies and an improved understanding of the molecular and cellular characteristics of OC are urgently needed. Here, we conducted a comprehensive analysis of primary tumor cells and their microenvironment from 16 chemonaive and 10 recurrent OC patient samples. Profiling OC tumor biomarkers allowed for the identification of potential molecular targets for developing immunotherapies, while profiling the microenvironment yielded insights into its cellular composition and property changes between chemonaive and recurrent samples. Notably, we identified CD1d as a biomarker of the OC microenvironment and demonstrated its targeting by invariant natural killer T (iNKT) cells. Overall, our study presents a comprehensive immuno-profiling of OC tumor and microenvironment during disease progression, guiding the development of immunotherapies for OC treatment, especially for recurrent disease. Elsevier 2023-09-19 /pmc/articles/PMC10558812/ /pubmed/37810241 http://dx.doi.org/10.1016/j.isci.2023.107952 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Li, Yan-Ruide Ochoa, Christopher J. Zhu, Yichen Kramer, Adam Wilson, Matthew Fang, Ying Chen, Yuning Singh, Tanya Di Bernardo, Gabriella Zhu, Enbo Lee, Derek Moatamed, Neda A. Bando, Joanne Zhou, Jin J. Memarzadeh, Sanaz Yang, Lili Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design |
title | Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design |
title_full | Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design |
title_fullStr | Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design |
title_full_unstemmed | Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design |
title_short | Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design |
title_sort | profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558812/ https://www.ncbi.nlm.nih.gov/pubmed/37810241 http://dx.doi.org/10.1016/j.isci.2023.107952 |
work_keys_str_mv | AT liyanruide profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT ochoachristopherj profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT zhuyichen profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT krameradam profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT wilsonmatthew profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT fangying profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT chenyuning profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT singhtanya profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT dibernardogabriella profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT zhuenbo profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT leederek profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT moatamednedaa profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT bandojoanne profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT zhoujinj profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT memarzadehsanaz profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign AT yanglili profilingovariancancertumorandmicroenvironmentduringdiseaseprogressionforcellbasedimmunotherapydesign |